Sydney, Australia, November 19, 2026
Clarity Pharmaceuticals has announced the completion of final follow-up assessments for all participants in its pivotal Phase III AMPLIFY clinical trial, evaluating the investigational radiopharmaceutical imaging agent ⁶⁴Cu-SAR-bisPSMA for detecting recurrent prostate cancer. This milestone moves the study into the next stage of data entry, analysis and preparation for reporting its clinical findings. AMPLIFY is designed to assess the diagnostic performance of copper-64-labelled SAR-bisPSMA using positron emission tomography (PET) and computed tomography (CT) in men experiencing biochemical recurrence (BCR) following initial definitive treatment for prostate cancer. The trial enrolled approximately 220 participants across clinical sites in the United States and Australia, with the recruitment target achieved in March 2026. According to the company, the last participant has now completed the required final follow-up assessments. The announcement represents an important step in Clarity’s clinical development programme, as the company prepares to evaluate whether its next-generation imaging technology can improve the detection and localisation of recurrent prostate cancer. The results are expected to support the potential regulatory development of ⁶⁴Cu-SAR-bisPSMA as a diagnostic imaging agent.
Phase III AMPLIFY Trial Completes Patient Follow-Up
The AMPLIFY study (NCT06970847) is a non-randomised, single-arm, open-label, multicentre Phase III diagnostic clinical trial investigating ⁶⁴Cu-SAR-bisPSMA PET imaging in men with rising or detectable prostate-specific antigen (PSA) levels following initial definitive treatment. The study focuses on patients with PSA levels above 0.2 ng/mL, a threshold used to identify biochemical recurrence following treatment. AMPLIFY commenced in May 2025, and the first participant was imaged at XCancer in Omaha, Nebraska, in the United States. The study subsequently reached its planned recruitment target of approximately 220 participants in March 2026. With all final follow-up assessments now completed, the clinical programme can progress towards the analysis of the collected imaging and clinical data. The trial is designed to evaluate the ability of ⁶⁴Cu-SAR-bisPSMA PET/CT to identify prostate cancer recurrence and provide information about the location of suspected lesions. This is particularly important for patients whose PSA levels begin rising after surgery or other definitive treatment, as identifying the location of recurrent disease can help physicians assess appropriate subsequent management strategies.
Diagnostic Endpoints Assess Same-Day and Next-Day Imaging
A central objective of AMPLIFY is to evaluate the diagnostic performance of ⁶⁴Cu-SAR-bisPSMA PET/CT at two different imaging time points. The study’s co-primary endpoints are the participant-level correct detection rate (CDR) and the region-level positive predictive value (PPV). These endpoints are assessed independently for same-day imaging, conducted approximately one to four hours after administration, and next-day imaging, performed approximately 24 hours after administration. The imaging schedule is intended to provide information about how the timing of PET scans influences the detection of prostate cancer lesions. The trial also includes exploratory endpoints, including comparisons of ⁶⁴Cu-SAR-bisPSMA with currently available standard-of-care prostate-specific membrane antigen (PSMA) PET imaging agents. PSMA is a protein frequently expressed at elevated levels on prostate cancer cells and serves as an important target for molecular imaging. By attaching copper-64 to its proprietary SAR-bisPSMA targeting structure, Clarity aims to produce a radiopharmaceutical capable of identifying PSMA-positive cancer lesions. The completed follow-up assessments will allow investigators to advance the planned evaluation of these diagnostic endpoints. However, the company has not yet reported the final AMPLIFY efficacy or diagnostic performance results.
Regulatory Progress and 2027 Data Milestones
Clarity’s broader development programme for ⁶⁴Cu-SAR-bisPSMA includes another registrational Phase III study, CLARIFY, which investigates its diagnostic performance in patients with prostate cancer who are candidates for definitive treatment. The AMPLIFY and CLARIFY programmes are intended to generate clinical evidence supporting potential regulatory applications to the U.S. Food and Drug Administration (FDA) for different prostate cancer imaging settings. In November 2026, ⁶⁴Cu-SAR-bisPSMA also received FDA Breakthrough Therapy Designation for PET imaging of PSMA-positive lesions in patients with suspected biochemical recurrence of prostate cancer. The designation recognises the potential of the investigational imaging agent and is intended to facilitate development and regulatory interactions. Clarity has indicated that topline data from the AMPLIFY and CLARIFY trials are expected in the first half of 2027. The company is also preparing for the regulatory submission process, including a planned rolling New Drug Application submission to the FDA. Importantly, ⁶⁴Cu-SAR-bisPSMA remains an investigational product, and its safety and efficacy have not yet been established through regulatory approval. Completion of AMPLIFY follow-up is therefore a significant development milestone, bringing Clarity closer to reporting pivotal clinical findings that could help determine the future role of advanced PSMA-targeted imaging in prostate cancer management.
Source: Clarity Pharmaceuticals press release



